The Myeloproliferative Neoplasm Symptom Assessment Form (MPN-SAF): international prospective validation and reliability trial in 402 patients
Mené auprès de 402 patients inclus dans des cohortes prospectives aux Etats-Unis, en Suède et en Italie, cette étude évalue un outil de mesure et d’analyse des symptômes des patients atteints de tumeurs myéloprolifératives et affectant leur qualité de vie
Symptomatic burden in myeloproliferative neoplasms is present in the majority of patients and compromises quality of life. We sought to validate a broadly applicable 18-item instrument (MPN-SAF, co-administered with the Brief Fatigue Inventory©) to assess symptoms of myelofibrosis (MF), essential thrombocythemia (ET) and polycythemia vera (PV) among prospective cohorts in the USA, Sweden and Italy. A total of 402 MPN-SAF surveys were administered (English (25%), Italian (46%) and Swedish (28%)) in 161 ET patients, 145 PV patients, and 96 MF patients. The majority reported that the MPN-SAF was easy to understand (98%) and "addressed most of my MPN symptoms" (96%). Responses between the three administered languages demonstrated great consistency after controlling for MPN subtype. Strong correlations existed between individual items and key symptomatic elements represented on both the MPN-SAF and the EORTC-QLQC30. Additionally, enrolling physicians' blinded opinion of patient symptoms (6 symptoms assessed) were highly correlated with corresponding patients' responses. Serial administration of the English MPN-SAF among 53 patients demonstrated that most MPN-SAF items are well correlated (r >0.5, p<0.001) and highly reproducible (ICC>0.7). The MPN-SAF is a comprehensive and reliable instrument which is available in multiple languages to evaluate symptoms associated with all types of MPNs in clinical trials globally.
Blood 2011